Indian scientists discover major breakthrough in combination drug
therapy to fight ovarian and breast cancer
Bolstering the
know how behind targeted cancer treatment, Indian scientists have offered a new
rationale for combination drug therapy for ovarian
cancer and breast cancer,
which they say can counter drug resistance and reduce side-effects.The insight
into molecular mechanisms of how the drug combination works to selectively hunt
down cancer cells with minimum effect on healthy cells is ‘highly relevant’ for
ongoing clinical trials, the researchers say.’Cancer specific-cell killing’ is
the most exciting change in the treatment strategy since the advent of the recent
personalised chemotherapy, contends senior scientist Benu Brata Das of the
Indian Association for the Cultivation of Science here.In that arena, Das and
his team worked on the two classes of drugs, PARP inhibitors and Top1
inhibitors, which exploit the cell’s own DNA repair machinery to kill cancer
cells.
The US FDA
recently approved Olaparib, a PARP inhibitor for ovarian cancer.’PARP
inhibitors (Poly ADP-ribose polymerase) have triggered immense interest in
clinical trials as a single agent for the treatment of breast and ovarian
cancer or in combination with DNA topoisomerase1 (Top1) inhibitors. However,
some of these patients develop resistance,’ Das told IANS.To overcome such
chemotherapeutic limitations, combination therapy (PARP + Top1 inhibitors) is
the ‘effective’ strategy, Das asserted.Further, the overarching idea of
combination therapy is to reduce side-effects in patients.’Combination therapy
generates synergy at low drug concentrations for selective killing of the
cancer cells,’ said Das, Assistant Professor & Wellcome-Trust/India
Alliance Fellow, Laboratory of Molecular Biology, IACS.But why go deep into the
cellular level to strengthen arguments for combination therapy? It all boils
down to ensuring the mechanism is safe and validated before patients can access
the drugs.’Understanding the molecular mechanisms of the combination treatment
is needed to be validated in the laboratory using cultured cancer cell and
animal models before it goes for clinical trials. So, development of new
rationale is important for the clinical combination of drugs before it directly
goes to the patients,’ Das explained.The synergistic clinical combination (PARP
inhibitors + Top1 inhibitors) is ‘relatively new’ and is mostly part of ongoing
clinical trials conducted by the US’s National Institutes of Health (NIH) and the
UK’s Cancer Research foundations, Das elaborated.’Patients in USA are
administered the combination of PARP + Top1 inhibitors relatively more in
comparison to the UK. The combination of PARP inhibitors (such as Veliparib;
ABT-888) and Top1 inhibitors (like Irinotecan) is effectively used for patients
with advanced breast carcinoma (BRCA1 and BRCA2 gene mutation), ovarian
carcinoma, metastatic lung cancer and triple-negative breast carcinoma,’ he
said.
In their study
published in the Nucleic Acids Research journal in July, the team comprising
Subhendu K. Das, Ishita Rehman, Arijit Ghosh, Souvik Sengupta, Papiya Majumdar,
Biman Jana from IACS showed how ABT-888 or Veliparib and camptothecin (a Top1
inhibitor) work in tandem to spike up toxicity to cancer cells.’Further studies
are warranted in different cancer models to establish the effective impact for
the combination therapy. We are hopeful for the effective clinical combination
of PARP1 and Top1 inhibitors in ovarian cancer patients and are actively
working in collaborating with the clinicians of the Tata Medical Centre-Cancer
Hospital (in Kolkata),’ Das added.According to molecular oncology and
therapeutics expert Bushra Ateeq of the Indian Institute of Technology-Kanpur,
the findings are ‘significant’ for developing novel therapeutic interventions
as PARP inhibitors are gaining momentum for the treatment of a variety of cancers
in combination with Top1 inhibitors.’This study will provide a new perspective
for the combinatorial therapy using PARP-inhibitors and Top1 inhibitors for the
treatment of breast or ovarian cancer patients harboring BRCA1/2 mutations,’
Ateeq, Assistant Professor, Department of Biological Sciences &
Bioengineering, IIT-Kanpur, told in an email.
Source: www.thehealthsite.com
Five ways to reduce your risk of heart disease!
New Delhi: Heart
disease, stroke and other cardiovascular diseases remain to be the top killer
of both men and women in the world. According to the American Heart
Association, heart disease is the number killer in the United States.
Heart
disease, coronary heart disease or CHD, has now become the leading cause of
mortality in India. Heat disease is a class of diseases that involve the heart
or blood vessels.
Although
some people are born with heart disease, there are many things you can do to
protect your heart and blood vessels by making some healthier lifestyle choices
such as:
·
Not
smoking – it’s the single best thing you can do for your heart health.
·
Being
physically active – regular physical activity can reduce your risk of
developing heart disease. It can also be a great mood booster and stress
buster.
·
Control
other health conditions, such as high blood pressure, high cholesterol and
diabetes to help prevent a heart attack or stroke.
Maintaining
a healthy weight as being overweight can increase your risk of a heart disease
and other health problem. In order to achieve an ideal weight, stick to a
healthy, balanced diet with plenty of fruits and vegetables while cutting down
on saturated fat, sugar and salt.
·
Reduce
and manage stress which increases the risk of heart attack.
Source: www.zeenews.india.com